The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, raised $20 million by offering 1.2 million ADSs at $16.75, within the range of $15 to $18. The company is currently listed on...read more
Updated Monday, 2/8. The IPO market is buzzing with 15 IPOs slated to raise $4.0 billion in the week ahead, led by dating app Bumble’s billion-dollar offering. Bumble (BMBL) plans to raise $1.7 billion at a $7.5...read more
Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, announced terms for its IPO on Tuesday. The company is currently listed on the Euronext Growth Paris (ALBPS). It previously filed to...read more
US IPO Weekly Recap: IPO frenzy brings the year’s largest deal and biggest pop in a 17 IPO week
The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
French biotech Biophytis prices US IPO at $16.75, within the range
Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, raised $20 million by offering 1.2 million ADSs at $16.75, within the range of $15 to $18. The company is currently listed on...read more
US IPO Week Ahead: Bumble’s billion-dollar deal leads a buzzy 15 IPO week
Updated Monday, 2/8. The IPO market is buzzing with 15 IPOs slated to raise $4.0 billion in the week ahead, led by dating app Bumble’s billion-dollar offering. Bumble (BMBL) plans to raise $1.7 billion at a $7.5...read more
French biotech Biophytis sets terms for $20 million US IPO
Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, announced terms for its IPO on Tuesday. The company is currently listed on the Euronext Growth Paris (ALBPS). It previously filed to...read more